This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UBX UNITY Biotechnology (UBX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About UNITY Biotechnology Stock (NASDAQ:UBX) Get UNITY Biotechnology alerts:Sign Up Key Stats Today's Range$0.20▼$0.2050-Day Range$0.18▼$0.8852-Week Range$0.20▼$1.23VolumeN/AAverage Volume808,608 shsMarket Capitalization$3.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Read More Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UBX Stock News HeadlinesUnity Stock Crashes Nearly 50% After Nasdaq Delisting NoticeJune 30, 2025 | finance.yahoo.comUnity Biotechnology stock plunges after Nasdaq delisting noticeJune 30, 2025 | za.investing.comUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)Unity Biotechnology Inc News (UBX) - Investing.comJune 26, 2025 | investing.comUBX Unity Biotechnology, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 6, 2025 | msn.comSee More Headlines UBX Stock Analysis - Frequently Asked Questions How were UNITY Biotechnology's earnings last quarter? UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings results on Tuesday, April, 22nd. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). When did UNITY Biotechnology's stock split? Shares of UNITY Biotechnology reverse split on the morning of Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did UNITY Biotechnology IPO? UNITY Biotechnology (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What other stocks do shareholders of UNITY Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK). Company Calendar Last Earnings4/22/2025Today7/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UBX CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees60Year Founded2009Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-246.82% Return on Assets-58.81% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book0.51Miscellaneous Outstanding Shares17,212,000Free Float16,214,000Market Cap$3.44 million OptionableOptionable Beta0.92 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:UBX) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UNITY Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share UNITY Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.